#United States #New York #Cancer Immunotherapy #NYU Langone #lipocalin 2

Exploring the Role of Stress-Induced Proteins in Cancer

Recent research conducted by a team led by NYU Langone Health has unveiled a potentially groundbreaking discovery in the field of oncology. The study focuses on a specific protein produced by stressed cancer cells, demonstrating its capability to assist lung and pancreatic tumors in evading immune detection. This revelation could significantly enhance the effectiveness of cancer treatments, particularly immunotherapies aimed at empowering the body's immune system to combat cancerous cells.

Understanding Cancer Cell Stress and Protein Production

The researchers delved into the underlying cellular mechanisms, specifically the integrated stress response (ISR) pathway, which enables cells to withstand stressful environments such as nutrient deprivation. Cancer cells, driven by their rapid and often unregulated growth, continually face such stressors, activating the ISR to survive. This pathway subsequently influences the production of a protein called Activating Transcription Factor 4 (ATF4).

ATF4 plays a vital role in the gene activation process that supports cancer cell survival. However, its influence extends beyond the cell; ATF4 serves as a precursor for the release of Lipocalin 2 (LCN2), which acts to shield tumors from immune system attacks. According to Thales Papagiannakopoulos, co-corresponding study author,